London
· Delayed Price · Currency is GBP · Price in USD KALA BIO Statistics
Total Valuation
KALA BIO has a market cap or net worth of GBP 28.79 million. The enterprise value is 18.91 million.
| Market Cap | 28.79M |
| Enterprise Value | 18.91M |
Important Dates
The next estimated earnings date is Monday, March 3, 2025.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +53.04% |
| Shares Change (QoQ) | +52.71% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 5.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.65 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.78 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 5.40.
| Current Ratio | 2.15 |
| Quick Ratio | 2.06 |
| Debt / Equity | 5.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.14 |
| Interest Coverage | -6.88 |
Financial Efficiency
Return on equity (ROE) is -430.96% and return on invested capital (ROIC) is -55.26%.
| Return on Equity (ROE) | -430.96% |
| Return on Assets (ROA) | -43.75% |
| Return on Capital (ROIC) | -55.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -676,053 |
| Employee Count | 43 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.20% |
| 50-Day Moving Average | 6.40 |
| 200-Day Moving Average | 6.80 |
| Relative Strength Index (RSI) | 54.21 |
| Average Volume (20 Days) | 232 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.08M |
| Pretax Income | -29.07M |
| Net Income | -29.07M |
| EBITDA | -29.89M |
| EBIT | -30.08M |
| Earnings Per Share (EPS) | -8.81 |
Balance Sheet
The company has 36.71 million in cash and 27.63 million in debt, giving a net cash position of 9.07 million.
| Cash & Cash Equivalents | 36.71M |
| Total Debt | 27.63M |
| Net Cash | 9.07M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.12M |
| Book Value Per Share | 1.11 |
| Working Capital | 20.45M |
Cash Flow
In the last 12 months, operating cash flow was -24.23 million and capital expenditures -108,931, giving a free cash flow of -24.34 million.
| Operating Cash Flow | -24.23M |
| Capital Expenditures | -108,931 |
| Free Cash Flow | -24.34M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.04% |
| Shareholder Yield | -53.04% |
| Earnings Yield | -100.99% |
| FCF Yield | -84.57% |
Stock Splits
The last stock split was on October 21, 2022. It was a reverse split with a ratio of 0.02.
| Last Split Date | Oct 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |